Hormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial.

Hdl Handle:
http://hdl.handle.net/10147/207767
Title:
Hormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial.
Authors:
Phelan, Niamh; O'Connor, Annalouise; Kyaw Tun, Tommy; Correia, Neuman; Boran, Gerard; Roche, Helen M; Gibney, James
Affiliation:
Department of Endocrinology, Adelaide and Meath Hospital, Incorporating the, National Children's Hospital, Dublin, Ireland.
Citation:
Am J Clin Nutr. 2011 Mar;93(3):652-62. Epub 2011 Jan 26.
Journal:
The American journal of clinical nutrition
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207767
DOI:
10.3945/ajcn.110.005538
PubMed ID:
21270384
Abstract:
BACKGROUND: Polycystic ovary syndrome (PCOS) is characterized by an adverse metabolic profile. Although dietary changes are advocated, optimal nutritional management remains uncertain. Polyunsaturated fatty acids (PUFAs), particularly long-chain (LC) n-3 (omega-3) PUFAs, improve metabolic health, but their therapeutic potential in PCOS is unknown. OBJECTIVES: We aimed to determine the associations between plasma PUFAs and metabolic and hormonal aspects of PCOS to investigate the efficacy of LC n-3 PUFA supplementation and to support the findings with mechanistic cellular studies. DESIGN: We selected a cross-sectional PCOS cohort (n = 104) and conducted a principal component analysis on plasma fatty acid profiles. Effects of LC n-3 PUFA supplementation on fasting and postprandial metabolic and hormonal markers were determined in PCOS subjects (n = 22) by a randomized, crossover, placebo-controlled intervention. Direct effects of n-6 (omega-6) compared with n-3 PUFAs on steroidogenesis were investigated in primary bovine theca cells. RESULTS: Cross-sectional data showed that a greater plasma n-6 PUFA concentration and n-6:n-3 PUFA ratio were associated with higher circulating androgens and that plasma LC n-3 PUFA status was associated with a less atherogenic lipid profile. LC n-3 PUFA supplementation reduced plasma bioavailable testosterone concentrations (P < 0.05), with the greatest reductions in subjects who exhibited greater reductions in plasma n-6:n-3 PUFA ratios. The treatment of bovine theca cells with n-6 rather than with n-3 PUFAs up-regulated androstenedione secretion (P < 0.05). CONCLUSIONS: Cross-sectional data suggest that PUFAs modulated hormonal and lipid profiles and that supplementation with LC n-3 PUFAs improves androgenic profiles in PCOS. In bovine theca cells, arachidonic acid modulated androstenedione secretion, which suggests an indirect effect of n-3 PUFAs through the displacement of or increased competition with n-6 PUFAs. This trial was registered at clinicaltrials.gov as NCT01189669.
Language:
eng
MeSH:
Adult; Androgens/*blood/metabolism; Animals; Biological Markers/blood; Cattle; Cells, Cultured; Cohort Studies; Cross-Over Studies; Cross-Sectional Studies; *Dietary Supplements; Double-Blind Method; Fatty Acids, Omega-3/blood/*metabolism/*therapeutic use; Fatty Acids, Omega-6/blood/metabolism; Female; Humans; Ovary/cytology/metabolism; Polycystic Ovary Syndrome/*blood/*diet therapy; Postprandial Period; Principal Component Analysis; Theca Cells/metabolism; Young Adult
ISSN:
1938-3207 (Electronic); 0002-9165 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorPhelan, Niamhen_GB
dc.contributor.authorO'Connor, Annalouiseen_GB
dc.contributor.authorKyaw Tun, Tommyen_GB
dc.contributor.authorCorreia, Neumanen_GB
dc.contributor.authorBoran, Gerarden_GB
dc.contributor.authorRoche, Helen Men_GB
dc.contributor.authorGibney, Jamesen_GB
dc.date.accessioned2012-02-01T10:47:55Z-
dc.date.available2012-02-01T10:47:55Z-
dc.date.issued2012-02-01T10:47:55Z-
dc.identifier.citationAm J Clin Nutr. 2011 Mar;93(3):652-62. Epub 2011 Jan 26.en_GB
dc.identifier.issn1938-3207 (Electronic)en_GB
dc.identifier.issn0002-9165 (Linking)en_GB
dc.identifier.pmid21270384en_GB
dc.identifier.doi10.3945/ajcn.110.005538en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207767-
dc.description.abstractBACKGROUND: Polycystic ovary syndrome (PCOS) is characterized by an adverse metabolic profile. Although dietary changes are advocated, optimal nutritional management remains uncertain. Polyunsaturated fatty acids (PUFAs), particularly long-chain (LC) n-3 (omega-3) PUFAs, improve metabolic health, but their therapeutic potential in PCOS is unknown. OBJECTIVES: We aimed to determine the associations between plasma PUFAs and metabolic and hormonal aspects of PCOS to investigate the efficacy of LC n-3 PUFA supplementation and to support the findings with mechanistic cellular studies. DESIGN: We selected a cross-sectional PCOS cohort (n = 104) and conducted a principal component analysis on plasma fatty acid profiles. Effects of LC n-3 PUFA supplementation on fasting and postprandial metabolic and hormonal markers were determined in PCOS subjects (n = 22) by a randomized, crossover, placebo-controlled intervention. Direct effects of n-6 (omega-6) compared with n-3 PUFAs on steroidogenesis were investigated in primary bovine theca cells. RESULTS: Cross-sectional data showed that a greater plasma n-6 PUFA concentration and n-6:n-3 PUFA ratio were associated with higher circulating androgens and that plasma LC n-3 PUFA status was associated with a less atherogenic lipid profile. LC n-3 PUFA supplementation reduced plasma bioavailable testosterone concentrations (P < 0.05), with the greatest reductions in subjects who exhibited greater reductions in plasma n-6:n-3 PUFA ratios. The treatment of bovine theca cells with n-6 rather than with n-3 PUFAs up-regulated androstenedione secretion (P < 0.05). CONCLUSIONS: Cross-sectional data suggest that PUFAs modulated hormonal and lipid profiles and that supplementation with LC n-3 PUFAs improves androgenic profiles in PCOS. In bovine theca cells, arachidonic acid modulated androstenedione secretion, which suggests an indirect effect of n-3 PUFAs through the displacement of or increased competition with n-6 PUFAs. This trial was registered at clinicaltrials.gov as NCT01189669.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAndrogens/*blood/metabolismen_GB
dc.subject.meshAnimalsen_GB
dc.subject.meshBiological Markers/blooden_GB
dc.subject.meshCattleen_GB
dc.subject.meshCells, Cultureden_GB
dc.subject.meshCohort Studiesen_GB
dc.subject.meshCross-Over Studiesen_GB
dc.subject.meshCross-Sectional Studiesen_GB
dc.subject.mesh*Dietary Supplementsen_GB
dc.subject.meshDouble-Blind Methoden_GB
dc.subject.meshFatty Acids, Omega-3/blood/*metabolism/*therapeutic useen_GB
dc.subject.meshFatty Acids, Omega-6/blood/metabolismen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshOvary/cytology/metabolismen_GB
dc.subject.meshPolycystic Ovary Syndrome/*blood/*diet therapyen_GB
dc.subject.meshPostprandial Perioden_GB
dc.subject.meshPrincipal Component Analysisen_GB
dc.subject.meshTheca Cells/metabolismen_GB
dc.subject.meshYoung Adulten_GB
dc.titleHormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial.en_GB
dc.contributor.departmentDepartment of Endocrinology, Adelaide and Meath Hospital, Incorporating the, National Children's Hospital, Dublin, Ireland.en_GB
dc.identifier.journalThe American journal of clinical nutritionen_GB
dc.description.provinceLeinster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.